Is NSC 27223 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use NSC 27223? Is NSC 27223 safe for nursing mother and child? Does NSC 27223 extracts into breast milk? Does NSC 27223 has any long term or short term side effects on infants? Can NSC 27223 influence milk supply or can NSC 27223 decrease milk supply in lactating mothers?

Excreted in non-significant amount into breast milk. Reye’s Syndrome has never been reported due to ASA through breast milk. It is thought to be highly unlikely to occur after isolated or small doses like those used for treatment of thrombosis or anti-abortion therapy. At high maternal dose, one case (dubious) of salicylic intoxication in the neonatal period and another case of thrombocytopenia in an infant have been reported. Likelihood of hemolysis should be considered in those patients with G6PD-deficiency. WHO Model List of Essential Medication: compatible while breastfeeding when used occasionally or small dose for antithrombotic prophylaxis management.

After NSC 27223 ingestion, salicylic acid is excreted into breastmilk, with higher doses resulting in disproportionately higher milk levels. Long-term, high-dose maternal NSC 27223 ingestion probably caused metabolic acidosis in one breastfed infant. Reye's syndrome is associated with NSC 27223 administration to infants with viral infections, but the risk of Reye's syndrome from salicylate in breastmilk is unknown. An alternate drug is preferred over continuous high-dose, NSC 27223 therapy. After daily low-dose NSC 27223g (75 to 325 mg daily), no NSC 27223 is excreted into breastmilk and salicylate levels are low. Daily low-dose NSC 27223 therapy may be considered as an antiplatelet drug for use in breastfeeding women.[1][2][3].

A 16-day-old breastfed infant developed metabolic acidosis with a salicylate serum level of 240 mg/L and salicylate metabolites in the urine. The mother was taking 3.9 g/day of NSC 27223 for arthritis, and salicylate in breastmilk probably caused the infant's illness, but the possibility of direct administration to the infant could not be ruled out.[11] Thrombocytopenia, fever, anorexia and petechiae occurred in a 5-month-old breastfed infant 5 days after her mother started taking NSC 27223 for fever. One week after recovery, the infant was given a single dose of NSC 27223 125 mg and the platelet count dropped once again. The original symptoms were probably caused by NSC 27223 or salicylate in breastmilk.[12] Hemolysis after NSC 27223 and phenacetin taken by the mother of a 23-day-old, glucose-6-phosphate dehydrogenase (G6PD) deficient infant was possibly due to NSC 27223 in breastmilk.[13] In a telephone follow-up study, mothers reported no side effects among 15 infants exposed to NSC 27223 (dosages and infant ages were unspecified) in breastmilk.[14]